IRE After Targeted Immunotherapy in HCC With Portal Vein Tumor Thrombus

This is a prospective, randomized, controlled, exploratory Phase II clinical study.Approximately 60 eligible patients with hepatocellular carcinoma and portal vein tumorthrombus who have received three cycles of target‐immunotherapy induction and havenon‐progressive disease will be enrolled. All patients must be considered unresectable orunable to tolerate surgical resection by MDT review and must provide written informedconsent. Participants will be randomized 2:1. Forty patients will undergo open orpercutaneous IRE followed by continuation of the original target‐immunotherapy regimen;twenty patients will continue the original treatment regimen alone. OS, PFS, tumorresponse, QoL, safety, and postoperative outcomes will be observed.